InSphero

Executive Summary

InSphero is a Swiss biotechnology company specializing in advanced 3D in vitro models for drug discovery and safety testing. Founded in 2009, the company develops scalable, reproducible spheroid-based models that replicate human liver, gastrointestinal, and tumor microenvironments, enabling more predictive preclinical testing. Its platform aims to reduce reliance on animal testing while accelerating the development of safer, more effective therapies. InSphero's technologies are applied across oncology, metabolic diseases, and toxicology, positioning the company as a key enabler of non-animal testing methods. With growing regulatory and industry push for physiologically relevant models, InSphero is well-placed to capture demand from pharmaceutical and biotech partners seeking higher predictivity in drug development. The company continues to expand its product portfolio and collaborates with leading research institutions to validate its models across diverse therapeutic areas.

Upcoming Catalysts (preview)

• Q4 2026Strategic Partnership with a Top Pharma for Liver Toxicity Testing60% success
• Q1 2027Launch of Next-Generation Tumor Organoid Panel for Immuno-Oncology50% success
• Q3 2026Regulatory Endorsement for 3D Models as Alternative to Animal Studies40% success